All In Biotech

Drug Trial Radar · NCT06904235

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

Jul 7, 2025

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed. The two substances are: palonosetron, an antagonist of 5 HT3 receptors, and fosnetupitant, an antagonist of NK1 receptors that transforms into netupitant in the body. The medication is administered through intravenous injection (IV- drip). This study is built from 2 parts: Part 1: phase 2, open label Part 2: phase 3 double blind The detailed description, study design, study milestones and eligibility criteria will reflect the Part 1 requirements

Conditions

  • Nausea and Vomiting Chemotherapy-Induced
  • Nausea Post Chemotherapy

Interventions

  • IV NEPA (fosnetupitant/palonosetron)Drug

    In NEPA-22-01, different body weight-based dosages of IV NEPA will be applied to patients below and over 3 months of age: Formulation A (for patients ≥3 months of age; 235 mg fosnetupitant/1.5 mg palonosetron per vial) or Formulation B (for patients \<3 months of age; 235 mg fosnetupitant/2.5 mg palonosetron per vial).

  • Reference Treatment: IV ondansetron infusionDrug

    IV Ondansetron Dosing Regimen * Day 1 (before start of chemotherapy): One 30-min infusion of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration) * Day 1 at 4 h and 8 h after the end of first administration: Two 30-min infusions of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)

  • Reference Treatment: IV fosaprepitant infusionDrug

    Fosaprepitant IV Dosing Regimen * Patients aged 12 years to \<18 years: a single dose of IV fosaprepitant 150 mg * Patients aged 2 years to \<12 years: a single dose of IV fosaprepitant 4 mg/kg (maximum dose: 150 mg) * Patients aged 6 months to \<2 years: a single dose of IV fosaprepitant 5 mg/kg (maximum dose: 150 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. COHORT 1 Neptupitant exposure parameterTime frame: From time zero ( start of IV NEPA infusion) to maximum 168 hours
  2. COHORT 1 Neptupitant exposureTime frame: From time zero ( start of IV NEPA infusion) to maximum 168 hours
  3. COHORT 2 monitoring of AEs (safety and tolerability of IV NEPA)Time frame: Up to 31 days

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Aghia Sophia Children's Hospital, Pediatric Hematology/ Oncology Unit (POHemU)

    Athens, Greece · Recruiting

  • "AHEPA" University General Hospital of Thessaloniki, 2nd Department of Pediatrics

    Thessaloniki, Greece · Withdrawn

  • Department of Pediatrics, Oncology and Hematology University Children's Clinical Hospital them. Ludwik Zamenhof in Bialystok

    Bialystok, Poland · Withdrawn

  • Department of Paediatrics, Haematology, Oncology and Rheumatology Voivodship Children's Hospital them. J. Brudziński

    Bydgoszcz, Poland · Recruiting

  • Clinic of Pediatrics, Oncology and Hematology University Pediatric Center them M. Konopnicka SP ZOZ Central Clinical Hospital Medical University of Lodz

    Lodz, Poland · Recruiting

  • University Children'S Hospital in Lublin, Department of Pediatric Hematology, Oncology, and Transplantology

    Lublin, Poland · Not yet recruiting

  • Clinical Department of Paediatric Oncology and Haematology VOIVODSHIP SPECIALIST CHILDREN'S HOSPITAL them. prof. dr. Stanisław Popowski in Olsztyn

    Olsztyn, Poland · Withdrawn

  • Department of Pediatric Oncology, Hematology and Transplantation Clinical Hospital them. Karol Jonscher Medical University them. Karol Marcinkowski in Poznań

    Poznan, Poland · Recruiting

  • Department of Paediatrics and Paediatric Haemato-Oncology University Clinical Hospital No. 1 them. prof. Tadeusz Sokołowski Pomeranian Medical University

    Szczecin, Poland · Withdrawn

  • Department of Paediatrics, Oncology and Paediatric Immunology, University Clinical Hospital No. 1 them. prof. Tadeusz Sokołowski Pomeranian Medical University in Szczecin

    Szczecin, Poland · Withdrawn

  • Department of Oncology and Surgical Oncology for Children and Youth Institute Mother and Child

    Warsaw, Poland · Recruiting

  • Department of Oncology Institute "Monument - Child Health Center"

    Warsaw, Poland · Recruiting

  • Fundeni Clinical Institute, Pediatric Hematology and BMT

    Bucharest, Romania · Recruiting

  • Oncology Institute "Prof. Dr. Al. Trestioreanu", Pediatric Oncology

    Bucharest, Romania · Recruiting

  • Emergency Children's Hospital " Louis Turcanu, Oncology-Haematology and BMP department

    Timișoara, Romania · Recruiting

  • Gazi University Gazi Hospital Children Hematology and Oncology

    Ankara, Turkey (Türkiye) · Recruiting

  • Hacettepe University Hospitals Oncology Hospital 2nd Floor Children Oncology

    Ankara, Turkey (Türkiye) · Recruiting

  • Istanbul University Istanbul Faculty of Medicine Topkapı

    Istanbul, Faith, Turkey (Türkiye) · Not yet recruiting

  • Ankara University Faculty of Medicine Children's Hospital, Department of Children Oncology and Hematology

    Ankara, Mamak, Turkey (Türkiye) · Recruiting

  • Erciyes University Hospitals Kanka Children's Hematology Oncology and Bone Marrow Hospital

    Kayseri, Melikgazi, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.